{
  "id": 4689300,
  "title": "TAVI-first strategy noninferior to a PCI-first strategy in patients with severe aortic stenosis and concomitant CAD",
  "url": "https://urgent.news/2026/08/31/tavi-first-strategy-noninferior-to-a-pci-first-strategy-in-patients",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T18:00:11.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-tavi-strategy-noninferior-pci-patients.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The TAVI-first strategy was found to be noninferior to a PCI-first strategy in patients with severe aortic stenosis and concomitant coronary artery disease, according to results from a randomized, noninferiority trial conducted at 48 centers across Europe. The study, presented at ESC Congress 2026 and published in the New England Journal of Medicine, included 986 patients with a mean age of 82 years. The primary endpoint, which included all-cause death, nonfatal myocardial infarction, ischemia-driven revascularization, valve-, procedure- or heart failure-related rehospitalization, or life-threatening, disabling or major bleeding at one year, occurred in 22.2% of patients in the TAVI-first group and 24.2% in the PCI-first group. There was no significant difference between the two groups, and the individual components of the primary endpoint were generally similar. Interestingly, fewer patients in the TAVI-first group ultimately underwent PCI, which was not due to impaired coronary access after TAVI but rather a change in clinical decision-making after the valve treatment.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}